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1. Introduction 
 
1.1 Definitions for bloodstream infections  
 
The exogenous and endogenous infections in the surgical departments and intensive care units 
are important health care challenges. These infections can lead to sepsis and septic shock 
indicating that this problem demands attention. While progress in prevention of these 
infections has been made, there are no complete solutions for nosocomial infections [1]. 
Sepsis is a potentially fatal whole-body inflammation caused by a severe infection [2]–[4].  
Sepsis is induced by the immune system’s response to a serious infection most commonly 
bacteria but also fungi, viruses and parasites in the blood, urinary tract, lungs, skin, or other 
tissues. Pneumonia is the most common cause of sepsis that accounts for half of all cases, 
followed by intraabdominal and urinary tract infections [5]. 
The reaction of the immune system to an infection also known as systemic inflammatory 
response system (SIRS). SIRS can be a response to a noninfectious offense as well, however, 
when it is the result of a confirmed infectious process, it is termed sepsis. Another definition 
for bloodstream infections is the bacteremia which means the presence of viable bacteria in 
the blood. The definitions viraemia, fungaemia and parasitemia are described in the same 
manner, respectively. The term septicemia, the presence of microorganisms or their toxins in 
the blood, is no longer used by the consensus committee [3]. 
The typical signs and symptoms of the sepsis are fever (>38oC) or hypothermia (<36oC), 
elevated heart rate (>90 beats per minute), rapid breathing (>20 breaths per minute or PaCO2 
<32 mm Hg) and the number of white blood cells (>12,000/cu mm, <4,000 cu mm, or > 10% 
immature (band) forms). The systemic response to an infection is manifested by two or more 
of these conditions. Further symptoms can be the confusion and the edema [2]. Sepsis is 
defined as severe when these findings occur in association with signs of organ dysfunction, 
such as hypoxemia, oliguria, lactic acidosis, elevated liver enzymes, and altered cerebral 
function [6].  
Following a bloodstream infections multiple organ dysfunction syndrome (MODS) than 
multiple organ failure (MOF) can evolve [7], [8]. 
Bloodstream infections are life-threatening, especially in individuals with serious underlying 
conditions or an impaired immune system [9]. Risk factors of sepsis can be divided into two/ 
three groups: risk factors for infection, contingent upon developing infection and possibility 
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for organ dysfunction [10], [11]. For example age, black race, male gender, health conditions 
are more susceptible to bloodstream infections. Moreover there is an inverse relationship 
between the socioeconomic status and the possibility of sepsis [12]. Severe sepsis most likely 
occurs in patients with chronic disease such as diabetes, cancer, chronic renal and liver 
disorders or obstructive pulmonary disease furthermore the residence in long-term care 
facilities, malnutrition, in addition the abnormalities in the immune response system can be 
risk factors for the infection [5]. 
 
1.2 Incidence of sepsis 
 
 The number of reported cases of bloodstream infections in the USA between 1979 and 2002 
was 10,319,418 and demonstrated an annualized increase of 8.7% [13]. This trend is expected 
to continue due to aging of the population, increased use of transplantation, 
immunosuppressive therapy, chemotherapy, and invasive procedures. The causative 
microorganism of sepsis is an important determinant of outcome, in addition in critically ill 
patients, the majority of infections are caused by bacteria. The most common Gram-positive 
isolates are Staphylococcus aureus and Streptococcus pneumonia, whereas Escherichia coli, 
Klebsiella species, and Pseudomonas aeruginosa predominate among Gram-negative isolates 
[14]. 
In the past three decades Gram-positive bacteria have shown increases in frequency of sepsis 
and are now almost as common as infections caused by Gram-negative bacteria [15], [16]. 
Figure 1.Numbers of cases of sepsis in the United States according to the causative 
oranism from 1979 to 2001 (Martin et al. 2003) [13] 
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During a 22 - year period incidence of Gram-positive infections increased by an average of 
26.3 percent per year [13]. 
However infection caused by Gram-negative bacteria have decreased - in a systemic literature 
review of 510 articles published during the last 30 years was reported that Gram-negative 
bacteremia was associated with a higher mortality compared with Gram-positive bacteremia 
[17]. In a more recent study involving 75 countries and 14,000 ICU patients, Gram-negative 
bacteria were isolated in 62% of patients with severe sepsis who had positive cultures, Gram-
positive bacteria in 47 % and fungi in 19% [18]. 
The most common bloodstream infections caused by Staphylococcus and E. coli were 
associated with a relatively low mortality (20% and 19%, respectively) compared with 
Candida (43%) and Acinetobacter (40%) species [19]. 
 However, fungal infections  account for only 4.6% of all infections, and they have a 
significant impact on public health, furthermore it has been found that the annual number of 
cases of sepsis caused by fungal organisms in the United States increased by 207% between 
1979 and 2000 [13]. Mixed fungal/bacterial infections are not uncommon, incidences of 
combined Candida and bacterial bloodstream infections have been reported in as many as 
23% of all episodes of candidaemia [20]. 
Despite its relatively low frequency, fungal blood stream infections can progress to severe 
sepsis and septic shock, associated with a drastic rise in mortality; therefore, early and 
appropriate treatment of such infections is critical [21]. Candida albicans is currently the 
most frequent causative agent of fungal sepsis, but the frequencies of invasive mycoses 
caused by C. parapsilosis, C. tropicalis, C. glabrata, C. kefyr, C. inconspicua and C. krusei 
have been reported to be increasing especially in immuncompromised patients [22], [23]. The 
majority of these mycoses-related deaths were associated with Candida, Aspergillus, and 
Cryptococcus sp. infection [13]. In vitro studies have indicated that emerging Candida species 
such as C. glabrata and C. krusei are demonstrating an increased incidence of resistance to 
antifungal agents, in particular to fluconazole [24], [25].  
Nowadays, a fourth of patients who develop severe sepsis will die during their hospitalization 
[26], [27]. In an epidemiological study where the authors analyzed the incidence, outcome 
and associated cost of care the average length of stay was 19.6 days and cost per case was 
$22,100 [5]. For this reason, the management of sepsis have great importance and the source 
of infection should be identified and controlled.  
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1.3 Current diagnosis of bloodstream infections 
 
According to the protocol used in case of bloodstream infections, bacteriological testing is 
performed in blood culture bottles. The patient’s blood is loaded into automated detection 
system that examines the production of CO2. Whenever microbial growth is suspected, blood 
is withdrawn from the positive bottle for sub culturing in plates, antibiotic susceptibility 
testing assessment (AST) and gram staining to provide the first identification. The bacterial 
identification is based on growth and culture characteristics, Gram-staining and further testing 
of biochemical properties [28].  
The detection of systemic fungal infections is difficult because the patient has only a few 
specific symptoms. In addition, the typical signs of the infection may be not present in the 
patient because of the immunosuppression of a patient. In case of fungi colonization is 
difficult to distinguish from invasive disease, blood culture is often negative and fungal 
identification depends on the microbial growth. Waiting for positive fungal blood culture 
results and potentially susceptibility testing leads to a significant delay in appropriate therapy 
and in turn higher mortality [29]–[31].  
It can be concluded that the entire procedure of identification the bacterial and/or fungal 
pathogens can be achieved in days because these methods require grown cultures [32]–[35]. 
Molecular identification after growth in blood culture media for example fluorescence in situ 
hybridization (FISH), polymerase chain reaction (PCR), ligase chain reaction (LCR), nucleic 
acid sequence based analysis (NASBA) provide faster identification of living bacteria 
compared to the gold standard culture based methods but it is still time-consuming because 
these molecular approaches are applied only following the positivity of the blood culture 
[36]–[39] (Figure 2). 
The availability of fast and reliable procedures for the differentiation of Candida species is 
another important issue for clinical laboratories. The diagnosis of candidaemia or 
haematogenous candidiasis can be problematic because of the low sensitivity of analysis via 
blood cultures [39]. Non-culturing methods, such as galactomannan antigenaemia, Western 
blotting and PCR based approaches are therefore being developed and evaluated for the 
detection of mycotic infections [40]–[42].  
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1.4 Why do we need improved methods? 
 
The main disadvantages of the standard culture techniques are the delay between blood 
sampling and information returned to the clinician (typically days), the need for 
bacteriological expertise, the personnel workload and reagent costs, as well as the inaccuracy 
of the method for detecting microorganisms that are fastidious or have been previously 
exposed to antibiotics. Moreover, the total hospitalization costs of sepsis are relatively high: 
there is an increase from $15.4 billion in 2003 to $24.3 billion in 2007 [43]. 
 
1.5 New possibilities in the diagnosis 
 
Molecular diagnostic methods for the detection of the pathogens have a continuously growing 
importance due to their rapidity and sensitivity. Different nucleic acid detection tests have 
been performed for detection of bloodstream infections such as FISH, NASBA, LCR, and 
PCR. [44]. 
Application of real-time PCR has revolutionized the way to diagnose human pathogens. 
Novel testing methods can combine PCR chemistry with fluorescent probe detection of 
amplified product in the same reaction vessel. The use of intercalating dyes allows the 
reaction kinetics (of the elongation step) and the amplicon melting point (Tm) to be 
determined easily. The intensity of the fluorescence emitted during the reaction correlates to 
the amount of DNA product formed. In general, both PCR and amplified product detection 
are completed in an hour or less, which is considerably faster than the conventional detection 
methods [45]–[50]. By now due to the innovation of the PCR machines, methods, 
polymerases, specific master mixes - detection of pathogens in different diseases is faster, 
reliable and more specific.  
 
1.5.1 Intercalating dyes, probes 
 
Intercalating dyes such as SYBR Green and Eva Green detect the accumulation of any double 
stranded DNA product. The use of intercalating dyes with appropriate instruments can 
perform a melting curve analysis to determine the melting temperature (Tm) which is sensitive 
but not always specific. The Tm is determined by the length of the amplicon and guanine 
cytosine content [51].  
Sensitive and specific detection is possible with real-time PCR by using novel fluorescent 
probes. In the clinical microbiology, the most frequently used probes are the Fluorescence 
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resonance energy transfer (FRET), TaqMan and Molecular Beacons. These detection methods 
all rely on the transfer of light energy between two adjacent dye molecules [52]. FRET 
technique is a distance dependent interaction between the electronic excited states of two dye 
molecules [53]. The excitation is transferred from a donor (anchor) molecule to an acceptor 
(quencher) molecule, without emission of a photon and has been proved to be an appropriate 
method for discriminating between the commonly occurring pathogen bacteria.  
 
1.5.2 Instruments 
 
The work load and work flow issues may determine which system could be the best for 
different-sized laboratories and test volumes. Thermocycling in lower capacity instruments 
such as LightCycler 1.2 (LC) (Roche Diagnostics GmbH, Mannheim, Germany) is faster than 
in instruments which use solid phase material for heat conductance (heating blocks) [54]. 
Selection of a real-time PCR instrument and real-time detection format requires consideration 
of test volume, probe detection conditions, turnaround time for results, personnel 
requirements, and software.  
The LightCycler machine demand special reaction vessels (20 μL sample capillary) and 
supports fluorescence resonance energy transfer hybridization probe detection with melting 
curve analysis. Our experiments are based on the use of LightCycler 1.2 because it is fast due 
to the air heating and cooling for the rapid temperature ramping and susceptible for FRET. 
These properties are let to analyze the most frequent causative agents of systemic infections, 
bacteria and fungi respectively.  
Real-time detection of a broad range fungal pathogens is possible by the use of Bio-Rad 
CFX96 (Bio-Rad Laboratories, Hercules, CA, USA) instrument which uses solid phase 
material for heat conductance and adaptable for High Resolution Melting analysis (HRM).  
  
1.5.3 New generation mixes 
 
Application of hot start DNA polymerases is popular and most often recommended for high-
throughput applications. The polymerases employed in Hot Start PCR are unreactive at 
ambient temperatures. Polymerase activity can be inhibited at these temperatures through 
different mechanisms, including antibody interaction, chemical modification and aptamer 
technology [55]. Usually activation of the polymerase is a 10 minutes step before the cycles. 
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These hot start polymerases are popular because of the specificity and grown sensitivity. In 
addition, some of our experiments were carried out without microbial nucleic acid 
purification due to the high temperature activation which is the same step as the cell wall 
disruption in high temperature and alkaline circumstances. After a 10 minutes digestion step 
the hot start polymerase can find free nucleic acid strands and starts the amplification [56].  
Another novelty is the commercially available “direct PCR” DNA polymerase which enables 
PCR amplification without any prior DNA purification from blood samples due to the 
resistance of the enzyme to inhibitors present in blood components. Application of master 
mixes with these polymerases can reduce the time requirement of a genetic analysis of a 
certain gene polymorphism. In order to facilitate the work flow and time requirements we 
have developed a rapid, simple and accurate procedure of genotyping from a single drop of 
animal blood without DNA preparation [57]. 
 
1.6 Existing nucleic acid based detection methods for the determination of the pathogens 
 
Molecular techniques have been developed in order to improve the sensitivity and to detect 
bloodstream infection earlier [58], [59]. The ideal molecular method would analyze the 
patient's blood sample and provide all the information required to immediately for direct 
optimal antimicrobial therapy in case of bacterial or fungal infections. Furthermore, it would 
provide data to assess the effectiveness of the therapy by measuring the clearance of microbial 
nucleic acids from the blood over time. None of the currently available molecular methods is 
sufficiently rapid, accurate or informative to fulfil this requirement. 
Several commercially available methods have been introduced, such as SeptiTest; (Molzym, 
Bremen, Germany), MolYsis (Molzym, Bremen, Germany), SeptiFast (Roche; Basel, 
Switzerland), Prove-it (Mobidiag, Helsinki, Finland), VYOO (Analytik Jena, Jena Germany) 
which can reduce the time required for the diagnosis [45]–[50]. Most of them use PCR for the 
identification of the pathogen. These techniques are similar to our system in some aspects, but 
they are usually based on previous culturing, they detect the causative microorganism after 
growth in blood culture bottles. 
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Figure 2. Possibilities for the detection of the microorganisms causing bloodstream 
infections. Compared to the gold-standard culture based method the pathogen specific PCR 
amplify the PCR product directly from blood without culturing the microorganisms. 
 
 
1.7 Novel molecular approach to detect the most frequent causative agents in sepsis 
 
In contrast to conventional blood culture methods and molecular techniques, which are 
applied following the positivity of the blood culture, there are novel approaches that allow the 
amplification directly from blood tubes. These techniques have the great advantage that they 
can detect the microorganisms in 2-5 h, have high sensitivity and the quantification of the 
bacterial load is possible [60]–[62].  
The LightCycler PCR assay is fast, reliable and relatively easy to perform - even in small 
laboratories. This method is based on a previously-reported FRET technique which has been 
proved to be an appropriate method for discriminating between the commonly occurring 
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pathogen Gram-positive and Gram-negative bacteria [63]. Differentiation of bacterial 
pathogens through a simple melting point analysis at 540 nm is impossible since there are no 
highly variable regions in the bacterial genome. For this reason the use of 16S rRNA coding 
region for the detection of the prokaryotic pathogens seems to be suitable [64].  
One approach for identification of the most common clinically relevant fungi is to find 
species or genus-specific genomic sequences such as heat shock protein 90 [65], aspartic  
 
proteinase [66], chitin synthase [67] or lanostherol synthase [68]. The use of RNA targets for 
the identification is rare [69]. However, it seems that the most effective solution for the 
differentiation of bloodstream infection related pathogens is the use of ITS (internal 
transcribed spacer) region (ITS1;ITS2) [70] [71]. These non-coding regions are highly 
variable rRNA coding regions which are adaptable for the identification of clinically relevant 
fungi over the broadest range. The ITS 2 region is situated between the 5.8S rRNA and 28S 
rRNA coding fraction and highly variable in different fungal species [72]. Due to the highly 
variable ITS 2 region is the 7 most frequent Candida species can be differentiated by the use 
of LC capillary real-time PCR, moreover the complete detection of 10 Candida and 4 
Aspergillus species, Cryptococcus neoformans, Fusarium oxysporum and Mucor hiemalis is 
possible through HRM (High Resolution Melting Analysis) and by the use of Bio-Rad CFX96 
real-time PCR machine [73]. The HRM is simply a precise warming of the amplicon DNA 
Figure 3. Internal Trascribed Spacer (ITS) – non coding sequences between rRNA 
coding regions (White et al. 1990, Somogyvári et al. 2007) [76], [80] 
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from around 50˚C up to around 95˚C. At some point during this process, the melting 
temperature of the amplicon is reached and the two strands of DNA separate or “melt” apart. 
The secret of HRM is to monitor this process happening in real-time. This is achieved by 
using intercalating dyes. Intercalating dye has unique property. When it binds specifically to 
double-stranded DNA it fluoresces brightly. In the absence of double stranded DNA 
intercalating dye has nothing to bind to and it only fluoresces at a low level. At the beginning 
of the HRM analysis there is a high level of fluorescence in the sample because of the billions 
of copies of the amplicon. But as the sample is heated up and the two strands of the DNA melt 
apart, presence of double stranded DNA decreases and thus fluorescence is reduced. The PCR 
machine which is adaptable for HRM detect this process by measuring the fluorescence. The 
machine then simply plots this data as a graph known as a melt curve. This curve shows the 
level of fluorescence vs. the temperature [74]. HRM is substantially used for genotyping. 
Real-time measurements of the fungal ITS 2 region is possible at 540 nm and require a non-
specific intercalating dye [75]. 
Until now, parallel detection of fungal and bacterial infections in the same reaction tube with 
real-time system has been an unresolved problem, however, there are several tests in the 
market with the same purpose. 
The differentiation of the bacterial pathogens, via melting temperature of the overall PCR 
product (by the use of 16S rRNA gene) and the melting point of the Gram specific probes, 
allow the creation of subgroups within the Gram-positive and Gram-negative strains. This 
system requires less than 4 h, inclusive of the time needed for the DNA preparation and the 
evaluation of the PCR results [76]. 
Real-time PCR detection can be performed by using free dyes or labelled sequence-specific 
probes. The novelty of our prototype system lies in the use of non-specific SYBR Green dye 
as a donor molecule, instead of a labelled primer or other specific anchor probe. This 
technique allows to examine pathogenic fungi, Gram-positive and Gram-negative bacteria in a 
single tube multiplex PCR reaction. Another novelty is the use of HRM analysis for the better 
discrimination of fungal infections and novel PCR mixes to reduce the time required for the 
differentiation of the pathogens involved in bloodstream infections. One combination of the 
two techniques uses unlabeled probes for the amplicon detection and Tm determination [77]. 
Another parallel application was the combination of TaqMan chemistry and the very new, 
aspecific dye, BOXTO, as a multiplex PCR [78]. 
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2. Aims of the study 
 
 
The purpose of this study was: 
 
 
 
 
- To find a rapid molecular biological tool for the detection of the bacterial and fungal 
pathogens which are currently the most frequent causative agents of bloodstream 
infections.  
 
- Optimization of the parameters of the reactions which enable to detect mixed bacterial 
and fungal infections in the same reaction tube.  
 
- Application of real-time PCR and FRET in order to differentiate of the pathogens in 
the same reaction vessel. 
 
- To establish a database with the tested microorganisms and with the appropriate Tm –s 
for the further analysis of unknown samples. 
 
- To set a broad range PCR for the better discrimination of the fungal pathogens by the 
use of HRM. 
 
- To detect the pathogens from EDTA blood or serum without gDNA purification. 
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3. Materials and methods 
 
3.1 Reference strains of the multiplex PCR 
 
Reference strains of 17 clinically relevant bacterial species were collected, as typical of the 
main causative agents of bloodstream infections [79]. Nine reference strains, Staphylococcus 
aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, Enterococcus faecalis 
ATCC 29212, Listeria monocytogenes ATCC 4701, Bacteroides fragilis ATCC 25285, 
Pseudomonas aeruginosa ATCC 27853, Haemophilus influenzae ATCC 49247, Escherichia 
coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603 were from the American Type 
Culture Collection [ATCC]. Streptococcus pyogenes OKI 80002 provided by the National 
Centre for Epidemiology, Hungary [OKI] and Proteus vulgaris HNCMB 60076 was from the 
Hungarian National Collection of Medical Bacteria [HNCMB]. Furthermore, to confirm the 
reliability and reproducibility of the technique, clinical strains of S. aureus (n = 4), S. 
epidermidis (n = 6), S. pyogenes (n = 2), E. faecalis (n = 2), E. faecium (n = 3), L. 
monocytogenes (n = 1), B. fragilis (n = 2), P. aeruginosa (n = 1), H. influenzae (n = 1), E. coli 
(n = 5), K. pneumoniae (n = 5), P. vulgaris (n = 3), Stenotrophomonas maltophilia (n = 2), 
Serratia marcescens (n = 2), Enterobacter aerogenes (n = 2), E. cloacae (n = 2) and 
Acinetobacter baumannii (n = 3) from the Institute of Clinical Microbiology at the University 
of Szeged, Hungary were also included. The species identities of the clinical isolates were 
confirmed by conventional biochemical methods. 
Ten fungal strains were examined in the same reaction vessel. Five reference strains, Candida 
albicans ATCC 10231 and ATCC 14053, C. tropicalis ATCC 750, C. parapsilosis ATCC 
22019 and C. glabrata ATCC 39316, were from the [ATCC], Cryptococcus neoformans IFM 
5844 and IFM 5855 were from IFM Quality Services Pty Ltd [IFM], and Aspergillus 
fumigatus SzMC 2486, A. flavus SzMC 2536 and A. niger SzMC 2761 were from the Szeged 
Microbiological Collection [SzMC]. Furthermore, clinical strains of C. albicans (n = 14), C. 
glabrata (n = 5), C. tropicalis (n = 4), C. parapsilosis (n = 5), C. krusei (n = 4), C. 
quillermondii (n = 4), C. lusitaniae (n = 3), C. norvegensis (n = 1), C. inconspicua (n = 2), C. 
dubliniensis (n = 2) and Cryptococcus neoformans (n = 2) from the Institute of Clinical 
Microbiology at the University of Szeged, Hungary were also tested. 
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3.2 Fungal reference strains of the HRM analysis 
 
The reference strains Candida albicans ATCC 10231 and ATCC 14053, C. tropicalis ATCC 
750, C. parapsilosis ATCC 22019, and C. glabrata ATCC 39316 were obtained from the 
American Type Culture Collection (ATCC, Manassa, VA, USA), Cryptococcus neoformans 
IFM 5844 and IFM 5855 were from IFM Quality Services Pty Ltd (IFM, Ingleburn, NSW, 
Australia) and Aspergillus fumigatus SzMC 2486, A. flavus SzMC 2536, A. niger SzMC 
2761, A. terreus SzMC 1932 were from Szeged Microbiological Collection (SzMC, Szeged, 
Csongrad, Hungary). 
To check the liability of the method, nonhuman pathogenic fungal strains Fusarium 
oxysporum SzMC 0609 and Mucor hiemalis SzMC 0478 were also examined. Furthermore, to 
confirm the reliability and reproducibility of the technique, clinical strains of C. albicans 
(n=14), C. glabrata (n=5), C. tropicalis (n=4), C. parapsilosis (n=5), C. krusei (n=4), C. 
quillermondii (n=4), C. lusitaniae (n=3), C. norvegensis (n=1), C. inconspicua (n=2), C. 
dubliniensis (n=2) and Cryptococcus neoformans (n=2) from the Institute of Clinical 
Microbiology at the University of Szeged, Hungary were also tested. These strains were 
maintained on BBL™ Sabouraud–chloramphenicol slant agar (Becton, Dickinson and 
Company, Sparks, MD, USA) and periodically sub-cultured. 24-h cultures were used for all 
subsequent experiments. The species identities of the clinical isolates were confirmed by 
conventional biochemical methods. 
 
3.3 Bacterial DNA purification 
 
The bacterial strains were grown on BBL™ Columbia agar plate (Becton, Dickinson and 
Company, Sparks, MD, USA) under aerobic conditions, except that Bacteroides fragilis was 
grown under anaerobic conditions. The bacterial DNA was extracted with the QIAamp® 
DNA Blood Mini Kit (QiaGene Inc, Chatsworth, Calif., USA), following the manufacturer’s 
instructions in “Protocols for Bacteria”. One milliliter of log-phase culture suspension, at a 
concentration of 107 CFU/mL, was used for the preparation. For determination of the 
sensitivity of the reaction, 100 μL of the serially diluted S. aureus reference strain was used 
for DNA extraction. The number of bacterial cells was determined by plating aliquots of 
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serially diluted samples onto BBL™ Columbia agar plate (Becton, Dickinson and Company, 
Sparks, MD, USA). 
For lysis of the rigid multilayered Gram-positive bacterial cell wall, we used a pre-incubation 
step with 20 mg/mL lysozyme (in 20 mM Tris • HCl, pH 8.0, 2 mM EDTA, 1.2% 
TritonX100). The spin protocol for “DNA Purification from Tissues” was followed, after 
incubation at 30°C for 30 min. The final concentration of DNA was 2.0-13.8 ng/μL, with a 
ratio A260/A280 = 1.6-1.8 after purification. 
3.4 Fungal DNA purification 
 
All the fungi were grown on BBL™ Sabouraud–chloramphenicol agar (Becton, Dickinson 
and Company, Sparks, MD, USA) medium. The fungal DNA was extracted from 1 mL of a 
log-phase culture suspension containing 9.6×107 of fungal cells. For determination of the 
sensitivity of the reaction, 100 μL of the serially diluted C. albicans reference strain was used 
for DNA extraction. The number of fungal cells was determined by plating aliquots of serially 
diluted samples onto Sabouraud-glucose agar. 
The QIAamp® DNA Mini Kit Protocol for Yeasts was followed in the DNA purification. In 
this case, additional reagents were required for elimination of the complex fungal cell-wall 
structure: sorbitol buffer (1 M sorbitol, 100 mM EDTA, 14 mM β-mercaptoethanol) [80] was 
used, and the samples were incubated with lyticase for 30 min at 30°C. Efficient and complete 
lysis was achieved in 1.5 hour in a shaking water-bath. This purification yielded 2.0–25 μg of 
DNA in 100 μL of water (2.0–13.8 ng/μL), with A260/A280 = 1.6–1.8. 
3.5 DNA preparation from infected blood 
 
Samples of 180 μL healthy donor bloods in EDTA tubes were infected with 20 μL of log-
phase culture suspension at a concentration of 108 CFU/mL bacterial and/or fungal cultures. 
Bacterial and fungal cells were quantified in Bürker chamber, by viable counts. For the 
sensitivity testing of the prototype system, the blood samples were infected with five dilutions 
of the log-phase culture suspension at a final volume of 20 μL. The first dilution contained 50 
copies in 1 μL template DNA (2.5x104 CFU/mL blood), the second contained 10 copies 
(5x103 CFU/mL blood), the third 5 copies (2.5x102 CFU/mL blood) and the fourth 2 copies 
(5x102 CFU/mL blood). The red blood cells were disrupted by lysis buffer [81], the bacterial 
and fungal cell wall lysed using the freezing-thawing method. After digestion with Proteinase 
K, the DNA extraction was carried out as reported previously [33]. 
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3.6 Bacterial and fungal primer design, FRET probes 
 
Two primer pairs were used for multiplex amplification of bacterial and fungal DNA. The 
bacterial primer pair was PLK1 (TAC GGG AGG CAG CAG) forward and PLK2 (TAT TAC 
CGC GGC TGC T) reverse, which are highly conserved in different groups of bacteria [63] 
and amplify the 16S rRNA sequence. The PLK2 reverse primer was modified and used 
without the inner fluorescence labelling. Originally, the labelled primer excited the Gram 
specific probes. We applied the non-specific SYBR Green dye for excitation; it also serves for 
visualization of the fungal amplicons. This primer-pair produces a 187 bp fragment in each 
species. 
Previously, hybridization probes were used for the Gram classification [76] ISN2 (5′-CCG 
CAG AAT AAG CAC CGG CTA ACT CCG T-3′) labelled with LCRed 640 was specific for 
Gram-negative, and ISP3 (5′-CCT AAC CAG AAA GCC ACG GCT AAC TAC GTG-3′) 
labelled with LCRed705. In our experiments ISP2 probe was labelled with Cy5.5 at the 5′ end 
which was specific for Gram-positive bacteria. The reason why we change the labeling dye 
because the producers offered Cy5.5 dye instead of LCred705. 
The ITS86 forward (GTG AAT CAT CGA ATC TTT GAA C) and the ITS 4 reverse (TCC 
TCC GCT TAT TGA TAG C) primers were used for detection of the fungi. These primers 
amplify a 192–494 bp sequence of ITS2 region, which is a highly variable part between the 
5.8S and 28S rRNA sequence [82]. 
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Primer/Probe Sequence (5’ – 3’) 
PLK 1  bacterial forward 
 
TAC GGG AGG CAG CAG 
PLK 2 bacterial reverse 
 
TAT TAC CGC GGC TGC T 
ITS 86 fungal forward 
 
GTG AAT CAT CGA ATC TTT GAA C 
ITS 4 fungal reverse 
 
TCC TCC GCT TAT TGA TAG C 
ISN 2 Gram-negative 
FRET probe 
 
                  CCG CAG AAT AAG CAC CGG CTA ACT CCG T 
ISP 3 Gram-positive 
FRET probe 
 
             CCT AAC CAG AAA GCC ACG GCT AAC TAC GTG 
Table 1. Sequences of the used primers and FRET hybridization probes. The probes were 
labelled on the 5’ end. 
 
3.7 Master mixes/excitation dyes 
 
Different, non-specific intercalating dyes are used for real-time PCR investigations. Most of 
these are accessible in ready-to-use, master mix formulae. Our goal was to choose the best 
dye for excitation of the labelled probes. The tested dyes were LCGreen “LightCycler® 480 
High Resolution Melting Master” (Roche Diagnostic GmbH, Mannheim, Germany); SYBR 
Green “LightCycler® 480 DNA Master SYBR Green I”, (Roche Diagnostics GmbH, 
Mannheim, Germany); “IQ™ SYBR® Green Supermix” (Bio-Rad Laboratries, Inc., 
Hercules, CA, USA) ; “Maxima™ SYBR Green qPCR Master Mix no ROX” (Fermentas, 
Vilnius, Lithuania); and “LC-FastStart DNA Master Hybridization Probes” (Roche 
Diagnostics GmbH, Mannheim, Germany) combined with EvaGreen dye (Biotium Inc., 
Hayward, CA, USA) and “Sso Fast™ EvaGreen® Supermix” (Bio-Rad Laboratries, Inc., 
Hercules, CA, USA). All master mixes were used according to the manufacturer’s 
instructions. 
LCred 
Cy5.5 
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3.8 Conditions of the multiplex real-time PCR 
 
Multiplex real-time PCR and FRET was performed using a LightCycler 1.2 real-time PCR 
instrument (Roche Diagnostics GmbH, Mannheim, Germany). The reaction volume of 10 μL 
contained 1 μL of DNA (with a final concentration of ~10 ng/μL), 1 μM of each of the 
primers, 0.7 μM of each of the probes, an appropriate amount of master mix, and 0.2 mM 
BSA (in the cases of the Fermentas and BioRad master mixes). 
The PCR conditions were as follows: initial denaturation at 95 °C for 600 s, followed by 40 
cycles of denaturation (95 °C for 0 s, 20 °C/s), annealing (55 °C for 15 s, 20 °C/s), and 
extension (72 °C for 20 s, 2 °C/s). The emitted fluorescence was measured after the annealing 
steps. The melting-curve analysis procedure consisted of 1 cycle at 95 °C for 10 s, 40 °C for 
120 s, followed by an increase in the temperature to 95 °C at 0.2 °C/s. The fluorescence signal 
(F) was monitored continuously during the temperature ramp, and plotted against temperature 
(T). 
 
3.9 Conditions of the broad range real-time PCR 
 
Bio Rad CFX96 real-time PCR instrument (Bio-Rad Laboratories, Hercules, CA, USA) was 
used for the amplification. The reaction volume of 10 μl contained 1 μl of fungal DNA, 1.0 
μM of each of the primers and 5 μl of reaction buffer, which includes EvaGreen dye (SsoFast 
Supermix; (Bio-Rad Laboratries, Inc., Hercules, CA, USA)). The PCR conditions were as 
follows: initial denaturation at 95 ˚C for 420 s, followed by 40 cycles of denaturation (95 ˚C 
for 30 s), annealing (55 ˚C for 60 s) and extension (72 ˚C for 60 s). The melting curve 
analysis at the end of the amplification consisted of one cycle starting at 72 ˚C for 20 s, the 
temperature subsequently being increased to 95 ˚C in 0.1 ˚C/s increments (HRM analysis).  
LightCycler DNA master SYBR Green I (Roche Diagnostics GmbH, Mannheim, Germany) 
master mix (MMX), Maxima qPCR SYBR Green no ROX (Fermentas Inc., Vilnius, 
Lithuania) MMX and the IQ SYBR Green Supermix (Bio Rad) MMX were also used for 
melting point investigations according to the manufacturer’s instructions. For comparison, the 
SYBR Green melting peak data were measured with the LightCycler real-time instrument 
(Roche Diagnostics GmbH), as described previously [75]. 
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3.10 Data analysis 
 
In case of multiplex real-time PCR and FRET melting peaks were evaluated using the 
LightCycler Software V 3.5. (Roche Diagnostic GmbH, Mannheim, Germany). The melting 
peaks were determined through the manual Tm option on the three detection channels (F1, F2 
and F3). 
The standard deviation (SD) of the melting-points was calculated from five parallel 
experiments.  
The sensitivity of the multiplex PCR calculated from five dilutions of the bacterial suspension 
monitored by the use of LightCycler Software V 3.5. 
The correct differentiation between bacteria and fungi was verified by means of gel 
electrophoresis, by the the amplicon length (fungal amplicons 192–494 bp, bacterial 187 bp). 
For the gel electrophoresis 1.5% agarose gel (AppliChem, Darmstadt, Germany) containing 
GelRed (10.000x in water) (Biotium Inc., Hayward, CA, USA) was used with HyperLadder™ 
DNA ladder 100-1013 kb (Bioline, London, UK). 
For the evaluation of the broad range PCR data Bio Rad CFX Manager Software version 1.6 
and Precision Melt Analysis Software 1.1 (Bio Rad) were used.  
Products of the direct PCR were loaded on to 1.5% agarose gel containing GelRed (10.000x 
in water) (Biotium Inc., Hayward, CA, USA), and data were evaluated with HyperLadder™ 
DNA ladder 100-1013 kb (Bioline, London, UK).  
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4. Results  
 
4.1 Discrimination of the fungal, Gram-positive and Gram-negative bacterial pathogens 
 
DNA samples from all species involved in the study were prepared successfully. The 
appropriate annealing temperature could be determined for the amplification of the bacterial 
and fungal template DNAs in the same reaction vessel. The pathogen templates amplified 
successfully the FRET probes of Gram-positives and – negatives could be excited by SYBR 
Green in LightCycler instrument. Species-specific Tm-s were obtained by melting-point 
analysis on three detection channels and all pathogens were identified succesfully as fungi or 
Gram negative or Gram positive bacteria (Table 1).  
At the F1 channel (540 nm), the melting points of all the amplicons (Tm A) were visible, due 
to the fluorescent signal of the SYBR Green non-specific intercalating dye. At the F2 (640 
nm) and F3 (705 nm) channels, the Gram-negative and the Gram-positive probes (Tm P), 
respectively, gave fluorescence signals. After the discrimination of the Gram-negative and 
Gram-positive strains, the fungal pathogens could be screened, because the fungal strains 
gave no signal at the F2 and F3 channels. 
Species specific human pathogenic fungal differentiation was obtained by High Resolution 
Melting (HRM) analysis. However, it requires another instrument and special software for the 
analysis, therefore the inchoation of prompt antifungal therapy is possible in a shorter 
diagnostic term.  
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Microbial strains 
 
Tm P 
(°C) 
Tm A 
(°C) 
Gram positive (G+) mean SD mean SD 
Enterococcus faecalis 67.94 0.07 84.14 0.36 
Enterococcus faecium 67.84 0.21 84.59 0.78 
Listeria monocytogenes 67.80 0.19 86.01 0.36 
Staphyloccus aureus 64.85 0.21 83.91 0.54 
Staphyloccus epidermidis 64.50 0.30 83.60 0.36 
Streptococcus pyogenes 46.54 0.56 84.38 0.78 
     
Gram negative (G-)        
Acinetobacter baumannii 66.09 0.15 82.90 0.16 
Bacteroides fragilis 48.65 0.18 84.47 0.84 
Enterobacter aerogenes 63.95 0.34 83.47 0.48 
Enterobacter cloacae 64.98 0.09 84.38 0.24 
Escherichia coli 64.69 0.44 84.74 0.54 
Haemophilus influenzae 61.99 0.35 84.28 0.30 
Klebsiella pneumoniae 65.13 0.23 84.57 0.20 
Proteus vulgaris 64.58 0.18 82.87 0.24 
Pseudomonas aeruginosa 53.32 0.33 83.00 0.34 
Serratia marcescens 64.01 0.30 84.17 0.30 
Stenotrophomonas maltophilia 58.10 0.07 84.42 0.15 
     
Fungi        
Candida albicans - - 87.1 0.33 
Candida dubliniensis - - 85.5 0.50 
Candida quillermondii - - 85.1 0.70 
Candida krusei - - 89.8 0.02 
Candida parapsilosis - - 85.4 0.88 
Candida tropicalis - - 84.5 0.75 
Aspergillus fumigatus - - 91.0 0.38 
Table 2. Melting points of bacterial and fungal amplicons and probes. All the amplicons 
Tm (Tm A) were measured at the F1 channel (540 nm). The signal was generated by aspecific 
SYBR Green dye. The Gram -positive specific probes produced a signal at the F2 channel 
(640 nm) the Gram-negative probes at the F3 channel (705 nm) (Tm P). The signals were 
induced with the help of a special FRET technique. 
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4.2 Determination of the bacterial pathogens 
 
Four Gram-positive and nine Gram-negative bacterial subgroups could be distinguished 
through a joint consideration of the melting points of the probes and the melting point of the 
overall PCR product (Figure 4). 
 
 
Figure 4. Differentiation of the bacterial pathogens. The group temperatures indicate the 
entire Tm of the pathogens. The subgroup temperatures are the melting temperatures of the 
hybridization probes. 
 
S. aureus and S. epidermidis have very close-lying melting temperatures and their species-
specific differentiation is not possible via this 16S rRNA coding sequence (Figure 5). A 
comparison of the Gene Bank sequences (S. aureus and S. epidermidis NCBI Taxonomy ID: 
NC_009782.1 and JF_799903.1) of these species revealed a variance of only three base-pairs, 
none of them were in the region where the probe is associated with the DNA. Thus, 
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determination of the clinically relevant Staphylococcus species requires other gene sequences, 
in which the antibiotic resistance can be detected [75]. Based on our experiments we could 
conclude that the two Enterococcus species show similar characteristics [73]. At the same 
time, S. pyogenes and L. monocytogenes are clearly differentiable. 
 
 
Figure 5. Melting peaks of Staphylococcus aureus and Staphylococcus epidermidis 
revealing that it is impossible to differentiate these Staphylococcus species via the Tm data of 
the amplicons or probes. 
 
Among the Gram-negative bacteria, E. coli is one of the most common causative agents of 
bloodstream infections [83]. Unfortunately, it has almost the same Tm as those of E. cloacae 
and S. marcescens. Other bacterial strains, such as H. influenza, can be differentiated through 
the melting temperature of the probe (Figure 6) or amplicon. The sensitivity of the reaction 
was five colony-forming units (CFU) per reaction. 
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Figure 6. Differentiation of Escherichia coli from Haemophilus influenzae. Although these 
pathogens have a very similar Tm in the 16S rRNA region, the Tm of the probes are clearly 
different. 
4.3 Determination of fungal pathogens  
 
Based on our results seven frequently-encountered fungal pathogens could be distinguished 
with LightCycler instrument. The highly variable ITS 2 target sequence allowed correct 
identification of all of the clinically relevant fungal strains, through the Tm determination on 
the F1 channel [84]. There was no signal on the F2 or F3 channel. The sensitivity of the 
reaction was 5 CFU per reaction. 
The correct differentiation between bacteria and fungi was verified by means of gel 
electrophoresis, with the help of the amplicon length (fungal amplicons between 192–494 bp, 
bacterial amplicons 187 bp). 
4.4 Determination of pathogens in the co-infection model 
 
In case of co-infections, there are some limitations in the detection. If the ratios of the 
different agents are higher than 1:10, the system does not detect the infectious agent which is 
in lower quantities. 
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4.5 Calibration of the multiplex PCR 
 
All three non-specific dyes (LCGreen, EvaGreen and SYBR Green) excited all of the labelled 
probes (LCRed640, LCRed705 and Cy5.5). The most significant results were obtained by the 
use of SYBR Green intercalating dye. 
The determination of Tm is very sensitive to the composition of the PCR reaction mixture, 
especially to the ionic strength. To avoid Tm bias due to the pipetting errors between PCR 
runs, the application of master mixes is recommended. Limitation of the method can be that 
various master mixes offered by different suppliers vary in reagent composition. This may 
influence the Tm values. 
Repeated runs with a certain master mix yield reproducible data. In case of different master 
mixes from different suppliers, calibration is necessary to establish the new Tm data on the 
fungal strains. 
The data obtained in this work by the use of multiplex real-time PCR were determined with 
the use of “Fermentas Maxima SYBR Green, no ROX” in five-eight parallel experiments. No 
false positive samples were found during the test phase of this method. No significant 
differences in the melting peak temperatures were observed between different isolates of the 
same species. The standard deviation of the melting peak temperatures for all 21 references 
and 93 clinical isolates included bacterial and fungal strains as well was between 0.08 and 
0.88, as listed in Table 1. These data are in concordance with our previous results [85], [86]. 
4.6 Sensitivity and reproducibility of the multiplex real-time PCR 
 
 For sensitivity testing of the prototype system, six bacterial and two fungal gDNA 
preparations were made from artificially infected blood. Eight species, and eight parallel 
investigations of five dilutions of blood containing bacterial suspensions were analyzed. Out 
of 8 reactions for each species, all of the reactions were positive with 50 DNA copies, 98.5% 
were positive with 10 copies, 67.2% were positive with 5 copies and 21.9% were positive 
with 2 copies (Table 3). All the reactions were carried out within the same parameters as 
described in the PCR conditions section. 
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*Out of 8 samples. 
   
 
 
4.7 Determination of fungal pathogens by HRM analysis 
 
DNA samples from all the fungal species involved in this study were prepared and amplified 
successfully using the EvaGreen dye-based method in the Bio Rad CFX instrument. Species 
specific melting peaks (Tm) were obtained via HRM analysis, allowing the differentiation of 
all investigated fungal species. Thus, it was possible to distinguish among the 15 most 
common fungal pathogens. The clinical strains had the same Tm as the references. Due to the 
highly saturating EvaGreen dye and the HRM analysis, the accuracy of the resolution was 
±0.01–0.24 ˚C. The sensitivity of the reaction was 5 CFU per reaction using the C. albicans 
reference strain. For comparison, all the fungal strains were investigated in the presence of the 
SYBR Green dye using the Roche LightCycler instrument. The sensitivity of the reaction was 
similar, but the SD was higher (±0.02-1.04 ˚C). The Tm data for the fungal strains are listed in 
Table 4. As mentioned before the determination of Tm is very sensitive to the composition of 
the PCR reaction mixture, and especially to the ionic strength. For example, the difference in 
Microbial strains 
No. (%) of positive PCRs*  
     Gram positive (G+) 50 copies 10 copies 5 copies 2 copies 1 copy 
Enterococcus faecalis 8 (100) 8 (100) 5 (62.5) 2 (25) 0 (0) 
Staphylococcus aureus 8 (100) 8 (100) 7 (87.5) 3 (37.5) 0 (0) 
Streptococcus pyogenes 8 (100) 8 (100) 5 (62.5) 5 (62.5) 0 (0) 
  
 
   Gram negative (G-)          
Enterobacter aerogenes 8 (100) 8 (100) 5 (62.5) 2 (25) 0 (0) 
Escherichia coli 8 (100)  8 (100) 6 (75) 1 (12.5) 0 (0) 
Haemphilus influenzae 8 (100) 7 (87.5) 4 (50) 0 (0) 0 (0) 
      Fungi           
Candida albicans 8 (100) 8 (100) 5 (62.5) 0 (0) 0 (0) 
Candida tropicalis 8 (100) 8 (100) 6 (75) 1 (12.5) 0 (0) 
      
Table 3. Diagnostic sensitivity of the PCR. Three Gram-positive, three Gram-negative and 
two fungal strains were used for the infection of healthy donor bloods. All the experiments 
were carried out eight times using 5 dilutions of the pathogens. 
. 
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Tm between C. albicans and C. dubliniensis was previously determined with the LightCycler 
DNA master SYBR Green I MMX to be 1.2 ˚C (87.4 and 86.2 ˚C) [75] . In case of Maxima 
qPCR SYBR Green no ROX MMX, the difference was 2.0 ˚C (83.5 and 81.5 ˚C), using the 
IQ SYBR Green Supermix it was 1.5˚C (85.6 and 84.1 ˚C) and with SsoFast Supermix it was 
1.0 ˚C (84.5 and 83.5 ˚C). The situation is similar for other fungi (data not shown). Repeated 
runs with a certain master mix yield reproducible data. In case of alteration of master mix, 
calibration is necessary to establish the new Tm data on the fungal strains, this is applied to 
bacterial investigations as well. The data determined with the broad range PCR were obtained 
by the use of SsoFast Supermix. 
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ND, Not determined; *data not published in the original article 
Table 4. Comparison of melting points of different fungal species. The previous studies 
used the LightCycler real-time PCR instrument, SYBR Green dye and melting analysis 
software. The present data were obtained by means of Bio Rad CFX Polymerase chain 
reaction machine, EvaGreen dye and High Resolution Melting analysis (HRM). The data 
were compared with data presented in previous articles [75], [82].  
Fungal species Melting temperature (°C)  
 HRM analysis Somogyvari et al. [75] Gutzmer et al. [82]  
 Mean SD Mean SD Mean SD  
Candida albicans  84.5 0.11 87.1 0.33 87.5 0.04  
C. glabrata 83.2 0.09 84.9 0.69 86.3 0.23  
C. guilliermondii 82.8 0.12 85.1 0.70 85.4 0.76  
C. parapsilosis 82.6 0.12 85.4 0.88 84.9 0.79  
C. tropicalis  81.8 0.05 84.5 0.75 84.7 0.77  
C. krusei 88.6 0.12 90.8 0.02 91.5 0.34  
C. lusitaniae 85.4 0.09 86.1* 0.30 ND   
C. norvegensis 86.2 0.22 86.1* 0.85 ND   
C. inconspicua 86.4 0.24 88.0 1.04 ND   
C. dubliniensis 83.5 0.12 85.5* 0.50 ND   
Cryptococcus neoformans 84.1 0.17 85.6* 0.96 ND   
Aspergillus niger 89.6 0.01 90.3* 0.95 93.9 0.10  
Fusarium oxysporum 85.4 0.16 ND  88.3 0.37  
Aspergillus fumigatus 90.9 0.14 91.0* 0.38 ND   
A. terreus ND  92.0* 0.53 ND   
A. flavus 90.4 0.15 90.4* 0.06 ND   
Mucor hiemalis 80.7 0.15 ND  ND   
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5. Discussions 
 
Sepsis and severe sepsis are the most common cause of death among critically ill patients in 
non-coronary intensive care units. Currently, real-time PCR is one of the fastest diagnostic 
method. Several commercially available PCR based method have been introduced, which can 
reduce the time necessary for the diagnosis. Most of them use PCR for the identification of 
the pathogen. These techniques are similar to our system in some aspects, but they are usually 
based on previous culturing, they detect the causative microorganisms after growth in blood 
culture bottles.  
In the following section, I would like to highlight the advantages and disadvantages of the 
commercially available detection kits: 
1.) SeptiTest; (Molzym, Bremen, Germany) can detect bacteria after DNA extraction, PCR 
amplification of target 16S rDNA, sequencing using sequencing primers. The last step is the 
evaluation of the data by using BLAST tool [87]. Compared to our method, this technique is 
not able to detect fungal pathogens. 
2.) MolYsis (Molzym, Bremen, Germany) has the great advantage in the buffer system which 
can eliminate the human DNA background before the purification of the pathogen nucleic 
acid. This test is specific for Enterobactericaceae, Pseudomonas aeruginosa, Staphylococcus 
Streptococcus and Enterococcus. The test performs more than one PCR for the correct 
detection of the bacteria moreover, the fungal identification is requires a parallel PCR. This 
fact increases the time of the identification [88], [89]. 
3.) SeptiFast (Roche; Basel, Switzerland) is the most commonly used PCR kit in case of 
whole blood analysis. It is very similar to our system but applies three parallel reaction 
vessels and requires a special software for the melting analysis and automated identification 
[90], [91]. 
 
4.) Prove-it (Mobidiag, Helsinki, Finland) is a combination of broad range PCR with 
amplification of resistance genes, because it detects the gyrB and pare topoisomerase genes 
and the mecA gene – to differentiate methicillin-susceptible from methicillin- resistance 
Staphylococcus aureus. It is a microarray based - technology after the PCR application [33]. 
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5.) VYOO (Analytik Jena, Jena Germany) is also combined microarray and resistance gene 
amplification method, because it applies a microarray technology and provides information 
about resistance within in 6-8 h. The great advantage of this technique is the elimination of 
the human DNA background in the first step [92]. 
The introduced prototype system uses two primer pairs and Gram specific hybridization 
probes for the multiplex real-time PCR. The use of rRNA genes for the detection of bacteria 
that can cause sepsis is based on the conserved 16S rRNA sequences of the bacteria. As 
regards fungi, the ITS sequence refers to a segment of non-functional RNA, situated between 
5.8S and 28S rRNAs. To confirm the results, it is possible to differentiate between fungi and 
bacteria, or between fungal species by electrophoresis [45], [93] or melting-point analysis 
[50]. The LightCycler PCR instrument was specially developed to amplify amplicons under 
500 bp. The regions amplified by PLK 1/ PLK 2 comprised 187 bp, while the fungal 
amplicons amplified by ITS 86 /ITS 4 primer pair varied between 192 bp (Geotrichum 
candidum) and 494 bp (Malassezia furfur), values which are perfectly suited to this 
instrument profile. 
As a novel element, excitation of the fluorescent probes was carried out with the help of a 
non-specific intercalating dye, this is an uncommon procedure in real-time investigations. It 
allows parallel detection of fungal pathogens and with bacteria in the same tube. As the result 
of the use of the multiplex PCR in combination with FRET probes and melting point-analysis, 
the broad-range identification of many frequent causative agents of bloodstream infections 
becomes possible within four hours. According to the literature the sensitivity of PCR in 
sepsis to detect the pathogens is generally between 3 and 100 CFU/mL [94]. In contrast the 
sensitivity of our prototype system was five CFU per reaction, which in combination with an 
efficient preparation is suitable for the detection of pathogens in bloodstream infections. If 
commercially available “Midi” preparation kits (i.e.: NucleoSpin Blood L, Macherey-Nagel, 
Düren, Germany) were used, the sample material was 2 mL of blood, the elution volume was 
100 μL and finally 5 μL of eluate were used for subsequent PCR. The calculated sensitivity 
was 50 CFU/mL in the blood sample. The sample/eluent ratio was equivalent in case of midi 
and maxi preparation kits which means that increased sample volume does not enhance the 
sensitivity [48]. The sensitivity of the “gold standard” conventional blood culture technique is 
one CFU per 10 mL blood sample [95]. We can conclude that our method is less sensitive. 
The blood culture technique is not replaceable with molecular techniques so far but the time 
delay until the adequate therapy can be reduce. 
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To determine the diagnostic sensitivity and reproducibility of the method, experiments with 
artificially infected blood were performed. The sensitivity of the PCR was 2 to 10 copies per 
reaction, which was the same as with cultured bacteria and fungi. The melting points (Tm A 
and Tm P) were the same as described in Table 3. using “Fermentas Maxima SYBR Green, no 
ROX”; therefore, human gDNA does not inhibit the reaction and does not modify the melting 
peaks. 
With this method, neither the Gram-positive S. aureus and S. epidermidis nor the Gram-
negative E. coli, E. cloacae and S. marcescens can be distinguished, and additional species-
specific probes or primers are necessary for the further differentiation of these species. 
Antibiotic resistance cannot be determined directly with this prototype system. The 
susceptibility testing of resistant E. coli strains can be performed using a PCR-based 
technique with other 16S rRNA specific primers [96]. Unfortunately, these investigations 
require a PCR analysis after the identification of the bacteria. 
In spite of its limitations, the prompt and reliable information provided by this new diagnostic 
method concerning the most common pathogenic bacteria might permit targeted therapy with 
narrow-spectrum antibiotics, instead of empirically-administered broad-spectrum antibiotics. 
To confirm these findings in clinical practice, a prospective study is now being designed. 
The incidence of sepsis has been continuously increasing over recent decades, and the early 
detection of the pathogens can have a great impact on the clinical outcome of infections [32], 
[97]–[99]. Molecular diagnostic systems allow species identification in less than 24 hours - 
which is a drastic improvement relative to the gold-standard, blood culture-based method and 
Gram staining-based identification methods that yield results in 24 to 72 hours [100], [101]. 
With the novel method described above, namely the multiplex PCR with the new combination 
of aspecific dyes and labelled probes, the most common causative agents of bloodstream 
infections can be detected in two hours, without DNA preparation; therefore, this method 
offers a great advantage over traditional FRET-based assays by detecting the Tm of both the 
probes and the amplicons accurately. 
As regards the broad range PCR, the same primers were used in HRM examinations because 
the shortest amplicons are more sensitive to the sequence alterations than the longer ones. 
High-resolution software is used for the detection and evaluation of mutations and 
polymorphisms in the short amplicons. In this context, users apply positive controls to 
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compare unknown PCR amplicons with chosen genotypes. This method can readily be 
applied to distinguish certain genetic alterations. The differentiation of the investigated fungal 
strains with the HRM software is more difficult. The software determines the relative ratios 
between the fluorescence curves, and thus all of the expected fungal species have to be used 
as positive controls in every PCR run. The melting peaks offer absolute values for the 
differentiation. The studies in the literatures indicate that in the case of yeasts, 99% of fungal 
septic infections are caused by eight species: C. albicans, C. tropicalis, C. glabrata, C. 
parapsilosis, C. krusei, C. guilliermondii, C. lusitaniae and Cryptococcus neoformans [102], 
[103]. These most common fungal pathogens can be differentiated with the help of melting 
peak differences. Furthermore, Aspergillus species can also be detected with this primer pair. 
The Tm values of the common fungal pathogens such as A. fumigatus, A. flavus and A. niger 
are different and their discrimination from Candida and from each other is possible (Table 4.).  
Additionally, we determined the Tm values of filamentous fungi which are non-pathogenic 
(M. hiemalis) or very rarely pathogenic (F. oxisporum) to humans. M. hiemalis can be easily 
distinguished, but F. oxysporum has same the Tm as that of C. lusitaniae. This illustrates that 
although this method is able to differentiate the most common fungal pathogens, it is not 
suitable as a general method of identification of fungal species. 
The fungal load in fungal sepsis is generally below 10 CFU/mL [104]. As the sensitivity of 
this PCR is 5 CFU per reaction, in combination with a correct preparation method, it is 
suitable for the detection of invasive Candida infections.  
The incidence of fungaemia has increased continuously in recent decades. The early detection 
of fungal pathogens has a great impact on the clinical outcome of the infection. We have 
improved the panfungal PCR by means of the HRM investigation, thereby achieving the 
distinction of 99% of fungal pathogens in sepsis. Thus, the protocol furnishes an opportunity 
for the rapid detection and reliable differentiation of the Candida and Aspergillus species 
most frequently isolated from clinical samples in bloodstream infections. 
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Summary 
 
The exogenous and endogenous infections in the surgical departments and intensive care units 
are important health care challenges. These infections can lead to sepsis and septic shock 
indicating that this problem demands attention. Since the gold standard blood culture based 
technique is time consuming and in case of fungi often yield false negative results due to the 
low sensitivity, molecular diagnostic methods have been introduced for the detection of 
pathogens related to sepsis. 
Polymerase chain reaction (PCR)-based techniques are widely used to identify fungal and 
bacterial pathogens causing serious infections. There have been numerous reports of different, 
new, real-time PCR-based pathogen identification methods although the clinical practicability 
of such techniques is not yet fully clarified. 
The thesis focuses on a novel, multiplex, real-time PCR-based pathogen identification system 
developed for rapid differentiation of the commonly occurring bacterial and fungal causative 
pathogens causing bloodstream infections and a real-time PCR detection method for the fast 
and reliable identification of fungal pathogens.  
A multiplex, real-time PCR approach was introduced for the detection and differentiation of 
fungi, Gram-positive and Gram-negative bacteria. The Gram classification is performed with 
the specific fluorescence resonance energy transfer (FRET) probes recommended for 
LightCycler capillary real-time PCR. The novelty of our system is the parallel amplification 
of bacterial and fungal pathogens in the same reaction vessel and the use of the non-specific 
SYBR Green dye instead of labelled anchor probes or primers, to excite the acceptor dyes on 
the FRET probes. In addition, the use of an intercalating dye allows the detection of fungal 
amplicons. For the better discrimination of the fungal pathogens we investigated a High 
Resolution Melting (HRM) analysis was applied that is used normally for allele 
discrimination. 
With the novel pathogen detection system, fungi, Gram-positive and Gram-negative bacteria 
in the same reaction tube can be differentiated within an hour after the DNA preparation via 
the melting temperatures of the amplicons and probes in the same tube. Furthermore, broad 
range detection of human pathogenic fungi could be possible with HRM technique. 
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The modified FRET technique and HRM are specific and more rapid than the gold-standard 
blood culture-based methods. Taking into account that the newly developed system is able to 
identify Gram-negative and – positive bacteria and fungi, this technique permit rapid and 
early evidence-based management of bloodstream infections in clinical practice. 
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Összefoglalás 
 
 
A műtéti osztályokon, de különösképp az intenzív terápiás részlegeken az endogén és exogén 
eredetű infekcióknak egyre nagyobb jelentőséget tulajdoníthatunk. Ezek a fertőzések 
szepszishez és szeptikus shock szindrómához vezethetnek. A diagnosztikai jellegű 
kutatásokban elért kielégítő eredmények ellenére sem sikerült teljesen megoldani a kórházi 
infekciók okozta problémákat. 
A polimeráz láncreakció alapú technikák széles körűen alkalmazhatók gombás és bakteriális 
fertőzések kimutatásához. Ez idáig rengeteg új real-time PCR alapú patogén detektálási 
módszert dolgoztak ki, habár a klinikai hasznosítása ezeknek a technikáknak még nem 
széleskörű. 
Jelen disszertáció egy új multiplex real-time PCR alapú identifikációs rendszert mutat be, 
mely speciálisan a vérárambeli bakteriális és gomba fertőzések gyors kimutatására 
alkalmazható továbbá egy még pontosabb gomba detektálásra alkalmas real-time PCR alapú 
technikát. 
Munkánk célja egy multiplex real-time PCR alapú technika kidolgozása volt, mely a gombák, 
Gram-negatív és Gram-pozitív baktériumok kimutatására szolgál. A Gram specifikus 
azonosítás FRET technikával történt, melynek kivitelezésére a LightCyler kapilláris real-time 
PCR készülék bizonyult a legalkalmasabbnak. Munkánk újdonsága a gombák és a 
baktériumok párhuzamos detektálásának lehetősége egy csőben. A kórokozók párhuzamos 
detektálásának sikeressége abban rejlik, hogy az interkaláló SYBR Green festék molekulával 
sikerült gerjeszteni a FRET próbákat, az interkaláló festék segítségével pedig a gomba törzsek 
is kimutathatók. A pontosabb elkülönítés érdekében High Resolution Melting analysis (HRM) 
alapú technikát dolgoztunk ki, mely alapvetően a genetikában használnak allél 
diszkriminációs vizsgálatokra. 
Az általunk kidolgozott patogén detektáló rendszerrel a gombák, Gram-pozitív és Gram-
negatív baktériumok párhuzamosan kimutathatók a DNS preparálást követő egy órán belül, 
olvadási hőmérséklet analízis segítségével: az amplikonok és a próba olvadási 
hőmérsékleteinek kombinációjából. Az általunk kidolgozott rendszer továbbá széles 
specificitású gomba detektálásra alkalmas real-time PCR és HRM technika segítségével. 
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A hagyományos tenyésztéses eljárások időigényesek és gombák érzékenységét tekintve 
érzékenységük nem megfelelő. Jelen módosított FRET technika és HRM analízis sikeressége 
a gyorsaságban és a specificitásában rejlik. A gombák és baktériumok egy csőben való 
azonosításának lehetősége gyors kimutatási technikát eredményez a jövőben. 
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New scientific results related to the thesis 
 
 
The newly developed LightCycler PCR assay is fast, reliable and relatively easy to perform - 
even in small laboratories. This method is based on a previously-reported FRET technique 
which has been proved to be an appropriate method for discriminating between the commonly 
occurring pathogen Gram-positive and Gram-negative bacteria.  
 
Bacterial pathogens, have been differentiated via melting temperature of the overall PCR 
product by the use of 16S rRNA gene and the melting point of the Gram specific probes, 
which allow the creation of subgroups within the Gram-positive and Gram-negative strains.  
 
The newly developed prototype system is based on the use of non-specific SYBR Green dye 
as a donor molecule, instead of a labelled primer or other specific anchor probe. 
 
Due to the highly variable ITS 2 region we 7 most frequent Candida species causing blood 
stream infections were differentiated by the use of LightCycler capillary real-time PCR. 
 
The complete detection of 10 Candida and 4 Aspergillus species, Cryptococcus neoformans, 
Fusarium oxysporum and Mucor hiemalis could be introduced by HRM (High Resolution 
Melting analysis) and by the use of Bio-Rad CFX96 real-time PCR machine.  
 
A novel method was estabilished to determine pathogenic fungi, Gram-positive and Gram-
negative bacteria in a single tube multiplex PCR reaction.  
 
The techniques described in this thesis provide a better discrimination of fungal infections and 
due to the novel PCR mixes the time required for the differentiation of the pathogens involved 
in bloodstream infections was reduced.  
 
The new system can provide a rapid detection method and can promote the adequate 
antibiotic therapy in bloodstream infections. 
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